Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / COM NEW
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
2,848,806
-
Shares change
-
-182,625
-
Total reported value, excl. options
-
$2,787,000
-
Value change
-
-$227,562
-
Put/Call ratio
-
0%
-
Number of buys
-
10
-
Number of sells
-
-14
-
Price
-
$0.9789
Significant Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q4 2016
48 filings reported holding GALT - GALECTIN THERAPEUTICS INC - COM NEW as of Q4 2016.
GALECTIN THERAPEUTICS INC - COM NEW (GALT) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,848,806 shares
.
Largest 10 shareholders include D.A. DAVIDSON & CO. (724,423 shares), VANGUARD GROUP INC (526,841 shares), Advisor Group, Inc. (370,825 shares), Benchmark Capital Advisors (198,200 shares), COURAGE CAPITAL MANAGEMENT LLC (130,000 shares), GEODE CAPITAL MANAGEMENT, LLC (108,237 shares), Neuberger Berman Group LLC (92,519 shares), US BANCORP \DE\ (90,834 shares), KCG HOLDINGS, INC. (84,603 shares), and BlackRock Fund Advisors (81,235 shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.